Moricizine

Moricizine
Moricizine
Systematic (IUPAC) name
ethyl [10-(3-morpholin-4-ylpropanoyl)-10H-phenothiazin-2-yl]carbamate
Clinical data
Trade names Ethmozine
AHFS/Drugs.com Consumer Drug Information
MedlinePlus a601214
Pregnancy cat. B (U.S.)
Legal status  ?
Pharmacokinetic data
Bioavailability 38%
Protein binding 95%
Half-life 3-4 hours (healthy volunteers), 6-13 hours (cardiac disease)
Identifiers
CAS number 31883-05-3 YesY
ATC code None
PubChem CID 34633
DrugBank APRD01124
ChemSpider 31872 YesY
UNII 2GT1D0TMX1 YesY
KEGG D05077 YesY
ChEBI CHEBI:6997 N
ChEMBL CHEMBL1075 YesY
Chemical data
Formula C22H25N3O4S 
Mol. mass 427.518 g/mol
SMILES eMolecules & PubChem
 N(what is this?)  (verify)

Moricizine (Ethmozine®) is a phenothiazine derivative with Vaughan Williams class Ic antiarrhythmic properties. It undergoes extensive first-pass metabolism, has a bioavailability of 34-38 percent, and is 95 percent bound to plasma proteins. Moricizine is extensively metabolized and may have pharmacologically active metabolites. A recent clinical study has shown that moricizine is slightly less effective than encainide or flecainide in suppressing ventricular premature depolarizations[citation needed]. Compared with disopyramide and quinidine, moricizine was equally or more effective in suppressing ventricular premature depolarizations, couplets, and nonsustained ventricular tachycardia[citation needed]. Further studies are needed comparing moricizine with other class 1 agents in the treatment of life-threatening arrhythmias; available data suggest that moricizine is comparable with these agents in the treatment of ventricular tachycardias and fibrillation. Moricizine appears to have a low incidence of serious adverse effects compared with other antiarrhythmics. This combination of apparently similar efficacy with a decreased incidence of adverse effects makes moricizine a worthwhile addition to currently available antiarrhythmic agents.

External links